T TITAN PHARMACEUTICALS
DEAD

Serial Number

87278812

Owner

TITAN PHARMACEUTICALS, INC.

Attorney

Jennifer Lee Taylor

First Use Date

Feb 26, 2019

Filing Date

Dec 22, 2016

Add to watchlist:

No watchlists yet
View on USPTO

T TITAN PHARMACEUTICALS Trademark

Serial Number: 87278812 • Registration: 5782129

T TITAN PHARMACEUTICALS is a trademark filed by TITAN PHARMACEUTICALS, INC. on December 22, 2016. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

TITAN PHARMACEUTICALS, INC. (37 trademarks)

400 OYSTER POINT BOULEVARD-SUITE 505
SOUTH SAN FRANCISCO, CA 94080

Entity Type: 03

Trademark Details

Filing Date

December 22, 2016

Registration Date

June 18, 2019

First Use Anywhere

February 26, 2019

First Use in Commerce

February 26, 2019

Published for Opposition

August 28, 2018

Cancellation Date

January 2, 2026

Goods & Services

Pharmaceuticals, namely, treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders and other serious and life-threatening diseases, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular disease, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based subdermal matrix formulation for the sustained release of drugs in the treatment of opiate addiction; pharmaceuticals, namely, implantable drug delivery system comprised primarily of a polymer-based matrix formulation for the sustained release of drugs in the treatment of central nervous system disorders and other serious and life-threatening diseases

Filing History

CANCELLED SEC. 8 (6-YR)
Jan 2, 2026 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 18, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
Jun 18, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
May 17, 2019 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
May 16, 2019 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 5, 2019 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 5, 2019 AITU
USE AMENDMENT FILED
Apr 23, 2019 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 23, 2019 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 19, 2019 EXRA
SOU EXTENSION 1 GRANTED
Apr 17, 2019 EX1G
SOU EXTENSION 1 FILED
Apr 17, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 17, 2019 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 23, 2018 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 28, 2018 NPUB
PUBLISHED FOR OPPOSITION
Aug 28, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 8, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 25, 2018 CNSA
EXAMINER'S AMENDMENT ENTERED
Jul 25, 2018 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 25, 2018 GNEN
EXAMINERS AMENDMENT E-MAILED
Jul 25, 2018 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jul 25, 2018 CNEA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Apr 17, 2018 RCSC
ASSIGNED TO LIE
Apr 13, 2018 ALIE
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Mar 28, 2018 ASCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 9, 2017 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 9, 2017 GNSL
SUSPENSION LETTER WRITTEN
Oct 9, 2017 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 15, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 15, 2017 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 15, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 29, 2017 GNRN
NON-FINAL ACTION E-MAILED
Mar 29, 2017 GNRT
NON-FINAL ACTION WRITTEN
Mar 29, 2017 CNRT
ASSIGNED TO EXAMINER
Mar 22, 2017 DOCK
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Jan 8, 2017 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 8, 2017 PARI
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 7, 2017 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 6, 2017 NWOS
NEW APPLICATION ENTERED
Dec 27, 2016 NWAP